| [1] |
Le XF,Bast RC Jr. Src family kinases and paclitaxel sensitivity[J].Cancer Biol Ther,2011,12(4):260-269.
|
| [2] |
Perez EA. Paclitaxel in breast cancer[J]. Oncologist,1998,3(6):373-389.
|
| [3] |
Wall ME,Wani MC,Taylor H. Plant antitumor agents, 27.Isolation, structure, and structure activity relationships of alkaloids from Fagara macrophylla [J]. J Nat Prod,1987,50(6):1095-1099.
|
| [4] |
McGrogan BT, Gilmartin B, Carney DN, et al. Taxanes,microtubules and chemoresistant breast cancer [J]. Biochim Biophys Acta,2008,1785(2):96-132.
|
| [5] |
Smoter M, Bodnar L, Duchnowska R, et al. The role of Tau protein in resistance to paclitaxel [J]. Cancer Chemother Pharmacol,2011,68(3):553-557.
|
| [6] |
Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer[J]. Proc Natl Acad Sci U S A,2005,102(23):8315-8320.
|
| [7] |
Tanaka S, Nohara T, Iwamoto M, et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer[J].Cancer Chemother Pharmacol,2009,64(2):341-346.
|
| [8] |
Liao CF, Luo SF, Shen TY, et al. CSE1L/CAS, a microtubule-associated protein, inhibits taxol ( paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs [J]. BMB Rep, 2008,41(3):210-216.
|
| [9] |
McKean PG, Vaughan S, Gull K. The extended tubulin superfamily[J].J Cell Sci,2001,114(Pt 15):2723-2733.
|
| [10] |
Verdier-Pinard P, Pasquier E, Xiao H, et al. Tubulin proteomics: towards breaking the code[J]. Anal Biochem,2009,384(2):197-206.
|
| [11] |
Kavallaris M. Microtubules and resistance to tubulin-binding agents[J].Nat Rev Cancer,2010,10(3):194-204.
|
| [12] |
Stengel C, Newman SP, Leese MP, et al. Class Ⅲbetatubulin expression and in vitro resistance to microtubule targeting agents [J]. Br J Cancer,2010,102(2):316-324.
|
| [13] |
Ganguly A, Yang HL, Cabral F. Class Ⅲ β-tubulin counteracts the ability of paclitaxel to inhibit cell migration[J]. Oncotarget,2011,2(5):368-377.
|
| [14] |
Kamath K,Wilson L,Cabral F, et al. Beta Ⅲ-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability [J]. J Biol Chem, 2005,280(13):12 902-12 907.
|
| [15] |
Banerjee A. Increased levels of tyrosinated alpha-, beta(Ⅲ)-,and beta(Ⅳ)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells[J].Biochem Biophys Res Commun, 2002,293(1):598-601.
|
| [16] |
Panda D, Miller HP, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition[J].Proc Natl Acad Sci U S A,1994,91(24):11 358-11 362.
|
| [17] |
Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer [J]. Ann Oncol,2005,16 Suppl 4:iv14-19.
|
| [18] |
Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins[J]. Int J Cancer,2007,120(10):2078-2085.
|
| [19] |
Wang H, Vo T, Hajar A, et al. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxelresistant MCF-7 breast cancer cells[J]. BMC Cancer,2014,14:37.
|
| [20] |
Wiesen KM, Xia S, Yang CP, et al. Wild-type class Ⅰbetatubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation [J]. Cancer Lett,2007,257(2):227-235.
|
| [21] |
Löwe J, Li H, Downing KH, et al. Refined structure of alpha beta-tubulin at 3.5 A resolution [J]. J Mol Biol, 2001,313(5):1045-1057.
|
| [22] |
Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain[J].Nature,2004,428(6979):198-202.
|
| [23] |
Yin S,Bhattacharya R,Cabral F. Human mutations that confer paclitaxel resistance [J]. Mol Cancer Ther, 2010, 9(2):327-335.
|
| [24] |
Wang Y, Yin S, Blade K, et al. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms[J]. Biochemistry,2006,45(1):185-194.
|
| [25] |
Ganguly A, Cabral F. New insights into mechanisms of resistance to microtubule inhibitors[J].Biochim Biophys Acta,2011,1816(2):164-1671.
|
| [26] |
Maeno K,Ito K,Hama Y, et al. Mutation of the class I betatubulin gene does not predict response to paclitaxel for breast cancer[J].Cancer Lett,2003,198(1):89-97.
|
| [27] |
Mulrane L, McGee SF, Gallagher WM, et al. miRNA dysregulation in breast cancer[J]. Cancer Res,2013,73(22):6554-6562.
|
| [28] |
朱安婕,袁芃.微小RNAs 在乳腺癌中的应用价值[J/CD].中华乳腺病杂志:电子版,2014,8(3):211-214.
|
| [29] |
Hu Q,Chen WX,Zhong SL, et al. MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells[J]. Tumour Biol,2014,35(7):6327-6334.
|
| [30] |
Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1)expression[J]. J Biol Chem,2010,285(28):21 496-21 507.
|
| [31] |
Zhong S, Li W, Chen Z, et al. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells[J].Gene,2013,531(1):8-14.
|
| [32] |
Mei M, Ren Y, Zhou X,et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells[J]. Technol Cancer Res Treat,2010,9(1):77-86.
|
| [33] |
Li M,Li J, Ding X, et al. MicroRNA and cancer[J]. AAPS J,2010,12(3):309-317.
|
| [34] |
Jiang YZ,Yu KD,Peng WT,et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel [J]. Nat Commun,2014,5:3802.
|
| [35] |
Vtorushin SV, Khristenko KY, Zavyalova MV, et al. The phenomenon of multi-drug resistance in the treatment of malignant tumors[J]. Exp Oncol,2014,36(3):144-156.
|
| [36] |
Shi JF,Yang N,Ding HJ,et al. ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERαpositive breast cancer cells in vitro and in vivo [J]. Int J Biochem Cell Biol,2014,53:35-45.
|